Why the study?
Myocardial fibrosis is caused by adverse cardiac remodeling after myocardial infarction, and RGS4 is involved in cardiac diseases by regulating GPCRs.
Does RGS4 inhibition or choline treatment reduce cardiac fibrosis in in vitro and in vivo models of myocardial infarction?
Population
TGF-beta1-treated cardiac fibroblasts in vitro and mice subjected to myocardial infarction in vivo
Comparison
Inhibition or overexpression of RGS4 and choline treatment
Design
In vitro and in vivo preclinical animal and cell study
Authors
Loading...
RGS4 inhibition should not yet alter post-MI care; hypothesis-generating for human fibrosis pathways.
Does RGS4 inhibition or choline treatment reduce cardiac fibrosis in in vitro and in vivo models of myocardial infarction?
RGS4 promotes cardiac fibrosis and blunts the protective effects of choline, highlighting a potential mechanistic pathway in post-myocardial infarction remodeling.
Guo et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: